Hornet Bite Management

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional, considering the individual patient's condition and circumstances. This reference does not replace professional medical judgment.

---

Overview

• Definition: A hornet bite refers to the injection of venom into the skin by a hornet (e.g., Vespa species), typically through a sting (hornets sting, they do not bite in the traditional sense of chewing). Hornet venom contains various pharmacologically active compounds that cause immediate pain, inflammation, and can trigger allergic reactions ranging from mild local symptoms to life-threatening anaphylaxis. Unlike bees, hornets can sting multiple times as their stingers are not barbed.
• Epidemiology:
  • Hornets are found globally, with various species (e.g., European hornet Vespa crabro, Asian giant hornet Vespa mandarinia).
  • Insect stings are a common cause of emergency department visits, with Hymenoptera (bees, wasps, hornets, ants) responsible for a significant proportion.
  • Approximately 0.4% to 0.8% of the general population may experience a systemic allergic reaction (anaphylaxis) to Hymenoptera venom.
  • Incidence of large local reactions can be as high as 10-20%.
  • Fatalities, though rare, are almost exclusively due to anaphylaxis, with an estimated 50-100 deaths per year in the United States.
  • Risk factors for severe reactions include a history of previous systemic reactions, age (extremes of age, particularly elderly), and underlying cardiovascular or respiratory conditions.
• Classification: Reactions to hornet stings are broadly classified into:
  1. Local Reactions: Pain, erythema, swelling (<10 cm diameter), and pruritus confined to the sting site, resolving within 24 hours.
  2. Large Local Reactions: Exaggerated local reactions characterized by swelling ≥10 cm in diameter, persisting for more than 24 hours (often 2-7 days). These are not IgE-mediated systemic allergic reactions.
  3. Systemic Allergic Reactions (Anaphylaxis): IgE-mediated reactions affecting organ systems distant from the sting site. Can range from mild cutaneous symptoms (urticaria, angioedema) to severe, life-threatening symptoms (respiratory distress, hypotension, cardiovascular collapse).
  4. Unusual Reactions: Less common responses, including serum sickness-like reactions, vasculitis, neurological complications (e.g., encephalitis), or renal failure, typically associated with multiple stings (massive envenomation).

Pathophysiology

• Mechanism: Hornet venom is a complex mixture of proteins, peptides, and biogenic amines. Key components and their effects include:
  • Phospholipases (A1 and B): Potent allergens that cause cell membrane damage, histamine release from mast cells and basophils, and contribute to inflammation and pain.
  • Hyaluronidase: An enzyme that breaks down hyaluronic acid in connective tissue, facilitating venom spread.
  • Kinins (e.g., bradykinin): Potent vasodilators that increase vascular permeability, leading to swelling and pain.
  • Histamine and Serotonin: Directly cause vasodilation, increased capillary permeability, and smooth muscle contraction (e.g., bronchospasm, gastrointestinal symptoms).
  • Acetylcholine: Neurotransmitter causing pain and some muscle contraction.
  • Mast Cell Degranulating Peptides: Directly trigger histamine release from mast cells, independent of IgE.
  • The immediate pain results from direct neurotoxic effects of venom components and activation of pain receptors by histamine, serotonin, and kinins. Swelling and redness are due to local inflammatory responses and vasodilation. Systemic allergic reactions involve the cross-linking of venom-specific IgE antibodies on mast cells and basophils, leading to widespread mediator release (histamine, leukotrienes, prostaglandins, platelet-activating factor), causing systemic vasodilation, increased vascular permeability, smooth muscle contraction, and organ dysfunction.
• Risk Factors:
  • Outdoor activities: Gardening, farming, hiking, camping increase exposure.
  • Proximity to nests: Disturbing hornet nests directly increases sting risk.
  • Prior sensitization: Previous hornet stings are necessary to develop IgE antibodies for systemic allergic reactions.
  • Atopy: Individuals with other allergic conditions (e.g., asthma, allergic rhinitis, eczema) may have a slightly increased risk of developing systemic reactions to stings, though this link is debated.
  • Older age: Increased risk of severe outcomes from anaphylaxis due to comorbidities (e.g., cardiovascular disease, concomitant medications).
  • Mastocytosis: Patients with mastocytosis are at a significantly higher risk for severe anaphylaxis to Hymenoptera stings, even with normal baseline tryptase levels.
  • Beta-blocker use: Can worsen anaphylaxis and make it refractory to epinephrine.
• Protective Factors:
  • Avoidance: Wearing long-sleeved shirts and pants outdoors, avoiding bright colors and strong perfumes/colognes, not walking barefoot in grassy areas, avoiding disturbing nests.
  • Vigilance: Awareness of surroundings when outdoors, especially near flowering plants or decaying fruit.
  • Prompt medical attention: Early recognition and treatment of anaphylaxis significantly improve outcomes.
  • Venom Immunotherapy (VIT): For individuals with confirmed IgE-mediated systemic reactions, VIT is highly effective in preventing future severe reactions.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Immediate, sharp, burning pain at the sting site.
  • Erythema (redness) and localized swelling (edema) around the sting.
  • Pruritus (itching) at the sting site.
  • A visible puncture mark.
• Early Signs (Local Reactions):
  • Pain, redness, and swelling confined to the area immediately surrounding the sting (typically <10 cm diameter).
  • Symptoms usually peak within hours and resolve within 24 hours.
• Advanced Signs (Large Local Reactions):
  • Swelling extending beyond the immediate sting site, often >10 cm in diameter.
  • May involve an entire limb or a significant portion of the face/neck.
  • Pain, redness, warmth, and itching can be intense.
  • Symptoms can persist for several days (typically 2-7 days).
  • Despite their severity, large local reactions are generally not dangerous unless swelling compromises a critical area (e.g., airway).
• Systemic Allergic Reactions (Anaphylaxis): These symptoms typically occur rapidly (minutes to a few hours) after the sting.
  • Cutaneous (most common): Generalized urticaria (hives), pruritus, angioedema (swelling of face, lips, tongue, eyelids), flushing.
  • Respiratory: Dyspnea (shortness of breath), wheezing, stridor, cough, hoarseness, throat tightness, sensation of impending doom.
  • Cardiovascular: Dizziness, lightheadedness, syncope (fainting), hypotension, tachycardia, arrhythmia, chest pain.
  • Gastrointestinal: Nausea, vomiting, abdominal cramps, diarrhea.
  • Neurological: Confusion, headache, anxiety.
• Atypical Presentations:
  • Delayed Hypersensitivity: Rare, typically presenting 24-48 hours later with a delayed urticarial or eczematous rash.
  • Serum Sickness-like Reactions: Very rare, occurring days to weeks post-sting, with fever, arthralgia, rash, and lymphadenopathy. Not IgE-mediated.
  • Kounis Syndrome: Angina or myocardial infarction triggered by anaphylaxis, due to coronary artery spasm or thrombus from inflammatory mediators.
  • Neurological manifestations: Encephalitis, peripheral neuropathy (very rare, usually with massive envenomation).
  • Renal: Acute kidney injury (rare, usually from massive envenomation or rhabdomyolysis).

Physical Examination

• Inspection:
  • Sting site: Look for a small puncture mark (hornets do not usually leave a stinger), erythema, and edema.
  • Skin: Assess for urticaria (wheals with surrounding flare), angioedema (non-pitting, often asymmetric swelling), flushing.
  • Respiratory: Observe for signs of respiratory distress (tachypnea, accessory muscle use, nasal flaring, stridor, wheezing).
  • Circulatory: Pallor, cyanosis, diaphoresis.
  • Mental status: Alertness, orientation.
• Palpation:
  • Sting site: Assess for warmth, tenderness, induration.
  • Skin: Check for non-pitting edema in angioedema.
  • Pulses: Assess peripheral pulses for rate, rhythm, and quality.
• Special Tests: No specific diagnostic tests are performed during the acute examination. The examination focuses on assessing the severity of the reaction and ruling out life-threatening complications.
  • Vital Signs: Blood pressure (hypotension is critical), heart rate (tachycardia or bradycardia), respiratory rate, oxygen saturation.
  • Airway assessment: Listen for stridor or hoarseness.
  • Auscultation of lungs: Listen for wheezing, rhonchi, or diminished breath sounds.
  • Cardiac auscultation: Assess for murmurs or gallops in severe cases.

Diagnostic Approach

History Taking

• Key Questions:
  • Timing and circumstances of sting: When and where did the sting occur? Was the hornet seen? Was a nest disturbed?
  • Number of stings: A single sting vs. multiple stings (massive envenomation).
  • Symptoms: Detailed description of all symptoms, including onset, progression, and severity.
    • Local (pain, swelling, redness, itching)?
    • Systemic (hives, swelling elsewhere, difficulty breathing, wheezing, dizziness, abdominal pain, vomiting, diarrhea)?
  • Previous reactions: History of prior hornet/wasp/bee stings and the nature of reactions (local, large local, systemic, anaphylaxis). This is crucial for risk stratification.
  • Medications: Current medications (especially beta-blockers, ACE inhibitors), recent antibiotic use.
  • Comorbidities: Asthma, cardiovascular disease, mastocytosis, chronic obstructive pulmonary disease.
  • Allergies: Known allergies to medications, foods, other insects.
  • Travel history: May indicate exposure to different hornet species.
• Red Flags: Symptoms indicating a systemic allergic reaction (anaphylaxis) requiring immediate emergency intervention:
  • Rapid onset of symptoms (within minutes to an hour).
  • Respiratory symptoms: Dyspnea, wheezing, stridor, throat tightness, hoarseness.
  • Cardiovascular symptoms: Dizziness, syncope, hypotension, weak pulses, pallor.
  • Widespread cutaneous symptoms: Generalized urticaria, angioedema away from the sting site.
  • Gastrointestinal symptoms: Severe abdominal pain, repetitive vomiting, diarrhea.
  • Altered mental status.

Laboratory Tests

• First-Line:
  • For local or large local reactions: No routine laboratory tests are needed.
  • For suspected anaphylaxis:
    • Serum Tryptase: A mast cell mediator that is elevated during acute anaphylaxis. A baseline tryptase should be drawn at presentation, ideally within 1-3 hours after symptom onset (peaks 1-2 hours), and a convalescent sample 24-48 hours later (or >24 hours later). An increase in tryptase from baseline can support the diagnosis of anaphylaxis. However, normal tryptase does not rule out anaphylaxis, especially if hypotension is not prominent.
    • CBC with differential: May show hemoconcentration in severe anaphylaxis due to fluid shifts. Eosinophilia is not acute but may be a chronic finding in atopic individuals.
• Confirmatory (for future risk assessment after systemic reaction):
  • Venom-specific IgE testing (ImmunoCAP/RAST): Measures circulating IgE antibodies to hornet venom (e.g., Vespa crabro, Vespa vulgaris). This test helps confirm sensitization and identify the specific venom (bee vs. wasp/hornet). It should be performed 2-6 weeks after the sting, as IgE levels may be transiently low immediately after a reaction.
  • Skin Prick Testing (SPT) or Intradermal Testing (IDT): Performed by an allergist, involves injecting dilute venom extract into the skin. A positive wheal-and-flare reaction indicates IgE sensitization. It is generally more sensitive than serum IgE and is typically performed by an allergist. Like serum IgE, it should be done several weeks after the acute reaction.
  • Baseline Serum Tryptase (repeat): To rule out underlying mastocytosis in patients with severe or recurrent anaphylaxis (a persistently elevated baseline tryptase suggests mast cell disorder).
• Monitoring:
  • In critical cases, monitoring of electrolytes, renal function (creatinine, BUN) may be necessary, especially with massive envenomation or prolonged hypotension.

Imaging

• Recommended: Generally not recommended for typical hornet sting reactions.
• Advanced:
  • Soft tissue ultrasound/CT: May be considered in cases of severe large local reactions with suspected secondary infection (e.g., abscess) or to rule out foreign body if there's uncertainty about a retained stinger (rare for hornets).
  • Neck CT/MRI: In severe angioedema of the airway, if intubation is being considered or there is concern for airway compromise and the extent needs to be evaluated. This is rare and typically clinical assessment and direct laryngoscopy are more immediate.
  • Chest X-ray: If there's persistent severe bronchospasm or concern for aspiration in unconscious patients.
  • Echocardiogram: In cases of suspected Kounis syndrome or significant cardiac compromise during severe anaphylaxis.

Management

Acute Management

• Immediate (within minutes):
  1. Remove the stinger: Unlike bees, hornets typically do not leave their stinger behind. If a stinger is observed, remove it quickly by scraping horizontally with a credit card or fingernail; avoid squeezing as this may inject more venom.
  2. Cleanse the area: Wash the sting site with soap and water to reduce the risk of secondary infection.
  3. Cold compress: Apply ice pack or cold compress to the sting site for 10-20 minutes to reduce pain, swelling, and venom absorption.
  4. Elevate the affected limb: If stung on an extremity, elevate it to help reduce swelling.
• Stabilization (Local and Large Local Reactions):
  1. Pain management: Oral analgesics such as acetaminophen (e.g., 500-1000 mg every 4-6 hours PRN) or NSAIDs (e.g., ibuprofen 400-600 mg every 6-8 hours PRN).
  2. Antipruritics: Oral H1 antihistamines (e.g., diphenhydramine 25-50 mg every 4-6 hours PRN, or non-sedating loratadine 10 mg daily/cetirizine 10 mg daily).
  3. Topical corticosteroids: Mild to moderate potency (e.g., hydrocortisone 1% cream, triamcinolone 0.1% cream) applied to the sting site 2-3 times daily to reduce inflammation and itching.
  4. Oral corticosteroids (for large local reactions): A short course of oral corticosteroids (e.g., prednisone 40-60 mg daily for 3-5 days, tapered if prolonged) may be considered for severe large local reactions to reduce swelling and discomfort, though evidence of efficacy is mixed.
  5. Monitor for infection: Advise patients to watch for signs of secondary bacterial infection (increasing pain, warmth, redness, purulent discharge, fever) and seek medical attention if these occur.
• Emergency (Systemic Allergic Reactions / Anaphylaxis): Rapid recognition and intervention are critical.
  1. Call for help: Activate emergency medical services (EMS) or rapid response team immediately.
  2. Primary Survey (ABCDE): Assess Airway, Breathing, Circulation, Disability (neurological status), Exposure.
  3. Epinephrine: This is the first-line and most critical treatment for anaphylaxis.
     • Route: Intramuscular (IM) into the mid-outer thigh (vastus lateralis muscle).
     • Dose:
       • Adults: 0.3-0.5 mg (0.3-0.5 mL of 1:1000 solution).
       • Children: 0.01 mg/kg (maximum 0.3 mg) of 1:1000 solution.
     • Repeat: May be repeated every 5-15 minutes if symptoms persist or recur. Do not delay repeat doses if needed.
  4. Positioning:
     • Supine: Lay patient flat with legs elevated to improve venous return (unless significant dyspnea or vomiting).
     • Pregnant patients: Left lateral recumbent position.
  5. Oxygen: Administer high-flow oxygen (6-8 L/min via facemask) to all patients with anaphylaxis.
  6. Intravenous Fluids: Rapid administration of isotonic crystalloids (e.g., normal saline 0.9% or lactated Ringer's) to combat hypovolemia and hypotension.
     • Adults: 1-2 liters rapidly, then adjust as needed.
     • Children: 20 mL/kg boluses, repeat as needed.
  7. Antihistamines:
     • H1-blockers: Diphenhydramine (IV 25-50 mg for adults, 1-2 mg/kg for children, max 50 mg) to reduce pruritus and urticaria.
     • H2-blockers: Ranitidine (IV 50 mg for adults, 1 mg/kg for children, max 50 mg) or famotidine (IV 20 mg for adults, 0.25 mg/kg for children, max 20 mg) may be given as adjuncts, though their role in acute anaphylaxis is less critical than H1-blockers.
  8. Corticosteroids:
     • To prevent biphasic reactions and reduce prolonged symptoms: Methylprednisolone (IV 1-2 mg/kg, max 125 mg) or oral prednisone (40-60 mg daily for 3-5 days). Administer after epinephrine and stabilization.
  9. Bronchodilators:
     • For bronchospasm: Nebulized short-acting beta-agonists (e.g., albuterol 2.5-5 mg for adults, 0.15 mg/kg for children, max 5 mg).
  10. Glucagon:
      • For patients on beta-blockers refractory to epinephrine: Glucagon can activate adenyl cyclase independent of beta-receptors. Administer 1-5 mg IV over 5 minutes for adults, followed by an infusion of 5-15 mcg/min.
  11. Observation: All patients with systemic reactions should be observed for at least 4-6 hours (or longer, up to 24 hours, depending on severity and initial response) due to the risk of biphasic anaphylaxis.
  12. Discharge planning: Prescribe and educate on epinephrine auto-injector use, medical alert bracelet, referral to an allergist.

Chronic Management

• Pharmacological:
  • Venom Immunotherapy (VIT): The only disease-modifying treatment for Hymenoptera venom allergy. Indicated for patients with a history of a confirmed IgE-mediated systemic reaction and positive venom-specific IgE or skin tests.
    • Mechanism: Gradually desensitizes the immune system to venom, reducing the severity or preventing future reactions.
    • Efficacy: Highly effective, reducing risk of systemic reactions from 50-70% to <5% for most patients.
    • Duration: Typically 3-5 years, but can be longer for those with high risk factors (e.g., mastocytosis, previous severe reaction).
  • Epinephrine Auto-injector (EAI): Prescribed to all patients with a history of systemic allergic reaction to Hymenoptera stings. Patients must be thoroughly educated on proper use, storage, and replacement. Two auto-injectors are often recommended.
• Non-pharmacological:
  • Avoidance strategies: As mentioned in protective factors.
  • Medical alert identification: Wearing a medical alert bracelet or necklace indicating venom allergy.
  • Education: Comprehensive patient and family education on recognizing symptoms of anaphylaxis, proper use of EAI, and when to seek emergency care.
• Monitoring:
  • Regular follow-up with allergist: For patients undergoing VIT, monitoring of symptoms, tolerance, and potential side effects. Reassessment of the need for EAI.
  • Annual review: For all patients with venom allergy, to review EAI expiration, technique, and avoidance measures.

Treatment Algorithms

• First-Line (Local Reactions):
  1. Remove stinger (if present).
  2. Cold compress.
  3. Oral analgesics (acetaminophen, NSAIDs).
  4. Oral H1 antihistamines.
  5. Topical corticosteroids.
• First-Line (Large Local Reactions):
  1. Same as local reactions (analgesics, antihistamines, topical corticosteroids).
  2. Consider short course of oral corticosteroids (e.g., prednisone 40-60 mg daily for 3-5 days).
  3. Monitor for secondary infection.
• First-Line (Systemic Allergic Reactions / Anaphylaxis):
  1. Epinephrine IM (mid-outer thigh): 0.3-0.5 mg adults, 0.01 mg/kg children (max 0.3 mg). Repeat every 5-15 min PRN.
  2. Call for emergency medical help.
  3. Supine position with legs elevated.
  4. High-flow oxygen.
  5. IV fluids (isotonic crystalloids).
  6. Adjunctive therapies: H1/H2 antihistamines, corticosteroids, bronchodilators as needed.
  7. Observation for 4-24 hours.
  8. Epinephrine auto-injector prescription and allergist referral on discharge.
• Second-Line (Refractory Anaphylaxis):
  1. Repeated epinephrine doses.
  2. Epinephrine infusion: If refractory hypotension or repeated IM doses are ineffective (e.g., 2-10 mcg/min for adults, 0.1-1 mcg/kg/min for children, titrated to response). Requires cardiac monitoring.
  3. Glucagon: For patients on beta-blockers.
  4. Vasopressors: Norepinephrine, dopamine, vasopressin for persistent hypotension despite adequate fluid resuscitation and epinephrine.
  5. Airway management: Intubation for impending airway obstruction.
• Refractory Cases:
  • Patients with recurrent or severe anaphylaxis despite optimal management and VIT may warrant further investigation (e.g., mastocytosis workup) and potentially extended VIT duration.
  • Consider consulting an immunology/allergy specialist.

Complications

• Common:
  • Secondary bacterial infection (cellulitis): From scratching the sting site, especially with large local reactions.
  • Persistent local swelling and pruritus: Can last for days to weeks.
  • Anxiety/Phobia: Fear of future stings, particularly after a systemic reaction.
• Serious:
  • Anaphylaxis: Life-threatening systemic allergic reaction with potential for airway obstruction, circulatory collapse, and multi-organ failure.
  • Airway obstruction: Due to angioedema of the larynx/pharynx or severe bronchospasm.
  • Hypotensive shock: Refractory hypotension from vasodilation and plasma leakage.
  • Myocardial infarction (Kounis syndrome): Acute coronary syndrome triggered by anaphylactic mediators.
  • Acute kidney injury: Rarely, from severe hypotension or rhabdomyolysis (in massive envenomation).
  • Rhabdomyolysis: Muscle breakdown, particularly with massive envenomation (>50 stings).
  • Disseminated Intravascular Coagulation (DIC): Extremely rare, usually associated with massive envenomation.
  • Neurological complications: Encephalitis, peripheral neuritis (very rare, usually with massive envenomation).
• Long-term:
  • Chronic anxiety and fear (entomophobia): Can significantly impair quality of life, leading to avoidance behaviors.
  • Recurrence of anaphylaxis: If proper preventative measures (EAI, VIT) are not followed.

Prognosis

• Factors:
  • Severity of initial reaction: Local reactions have an excellent prognosis. Systemic reactions vary significantly based on initial severity and rapidity of intervention.
  • Promptness of treatment: Early administration of epinephrine for anaphylaxis significantly improves outcomes.
  • Number of stings: A higher number of stings increases the risk of both toxic (non-allergic) and allergic reactions.
  • Underlying comorbidities: Patients with cardiovascular disease, asthma, or mastocytosis are at higher risk for severe or fatal outcomes.
  • Age: Extremes of age, particularly the elderly, are at increased risk due to reduced physiological reserves and comorbidities.
• Survival:
  • Local reactions: Excellent prognosis, full recovery.
  • Systemic reactions: With prompt and appropriate medical intervention (especially epinephrine), the prognosis is generally good. Fatalities are rare but primarily occur due to delayed or inadequate treatment of anaphylaxis.
  • Massive envenomation (>50 stings): Can lead to direct toxic effects on multiple organs (renal, hepatic, hematological, neurological, cardiovascular), increasing morbidity and mortality regardless of allergic status.
• Quality of Life:
  • Individuals who have experienced systemic reactions may suffer from significant anxiety, leading to altered lifestyle choices and reduced quality of life, even if their physical health is good.
  • Successful venom immunotherapy greatly improves quality of life by reducing the fear of re-sting and allowing patients to resume normal activities.

Prevention

• Primary (Preventing Initial Occurrence):
  • Avoidance:
    • Steer clear of known hornet nests. If a nest is found near human activity, professional extermination should be considered.
    • Avoid sudden movements if a hornet is nearby.
    • Wear long-sleeved shirts, long pants, socks, and shoes when outdoors, especially in areas with flowering plants or near potential nesting sites.
    • Avoid bright-colored clothing, strong perfumes, colognes, scented lotions, and hair sprays, which can attract hornets.
    • Be cautious when eating outdoors; keep food covered and clear away food scraps promptly.
    • Do not drink directly from open cans or bottles outdoors, as hornets can crawl inside. Use a straw or clear cup.
    • Keep garbage cans tightly covered.
    • Inspect areas before working (e.g., gardening, pruning).
    • Keep car windows closed when driving through rural areas.
• Secondary (Early Detection and Intervention):
  • Epinephrine Auto-injector (EAI): Patients with a history of systemic allergic reactions should always carry two EAIs and know how to use them. Family members and close contacts should also be educated.
  • Medical Alert Identification: Wear a medical alert bracelet or necklace indicating the allergy.
  • Education: Thoroughly educate patients on the signs and symptoms of anaphylaxis and the importance of immediate epinephrine administration.
• Tertiary (Preventing Complications):
  • Venom Immunotherapy (VIT): For individuals with confirmed IgE-mediated systemic reactions, VIT is highly effective in preventing future severe reactions and should be strongly considered.
  • Follow-up: Regular follow-up with an allergist/immunologist for management of venom allergy and monitoring of VIT.

Special Populations

• Pediatric:
  • Epinephrine Dosing: 0.01 mg/kg IM (maximum 0.3 mg) of 1:1000 solution. Pre-dosed auto-injectors come in 0.15 mg (for children 10-25 kg) and 0.3 mg (for children >25 kg) formulations.
  • Anxiety: Children may experience significant anxiety or phobia after a sting, requiring psychological support.
  • Education: Education on avoidance and auto-injector use for both the child and caregivers is paramount.
• Geriatric:
  • Increased Risk: Elderly patients are at higher risk for severe complications from anaphylaxis due to increased prevalence of cardiovascular disease, respiratory conditions, and use of medications (e.g., beta-blockers, ACE inhibitors).
  • Medication Interactions: Beta-blockers can blunt the response to epinephrine and increase the risk of severe, refractory anaphylaxis. Glucagon should be considered. ACE inhibitors may also worsen angioedema.
  • Comorbidities: Careful consideration of underlying conditions when managing anaphylaxis.
  • Dexterity: May have difficulty using auto-injectors; ensure proper training and alternative assistance if needed.
• Pregnancy:
  • Epinephrine Safety: Epinephrine is safe and indicated for anaphylaxis during pregnancy. The risk of untreated anaphylaxis to both mother and fetus far outweighs any theoretical risks of epinephrine.
  • Positioning: Pregnant patients should be placed in the left lateral recumbent position to avoid supine vena cava compression.
  • Avoidance: General avoidance measures are key.
  • VIT: Generally considered safe during pregnancy if initiated before pregnancy, but usually not initiated during pregnancy.
• Comorbidities:
  • Asthma: Patients with asthma are at higher risk for severe respiratory symptoms during anaphylaxis. Ensure quick access to bronchodilators and reinforce asthma action plans.
  • Cardiovascular Disease: Increased risk of Kounis syndrome and cardiac arrhythmias during anaphylaxis. Careful monitoring and management of hemodynamics are crucial.
  • Mastocytosis: Patients with mast cell disorders (cutaneous or systemic mastocytosis) are at significantly increased risk of severe, prolonged, or recurrent anaphylaxis to Hymenoptera stings, even with normal baseline tryptase levels. Venom immunotherapy is highly recommended for these patients, often with prolonged duration. They may require higher or more frequent epinephrine doses.

Clinical Pearls

• Diagnostic:
  • Epinephrine first: Do not delay epinephrine administration for anaphylaxis while waiting for diagnostic certainty or other medications.
  • Tryptase levels: Useful for supporting a diagnosis of anaphylaxis but do not rule it out if normal, especially in cases where hypotension is not the predominant feature. Obtain acute and baseline levels.
  • Large local vs. cellulitis: Large local reactions can mimic cellulitis; look for the immediate onset and typical sting appearance. Cellulitis typically develops hours to days later, with progressive erythema, warmth, and tenderness, often without the pruritus seen in allergic reactions.
• Treatment:
  • Dose epinephrine correctly: Underdosing is a common mistake. Use IM administration in the mid-outer thigh.
  • Observation period: A minimum of 4-6 hours (and sometimes longer, up to 24 hours) of observation is crucial after a systemic reaction due to the risk of biphasic anaphylaxis.
  • Patient education: Ensure patients and caregivers are thoroughly educated on how and when to use an epinephrine auto-injector, and to call emergency services after using it.
  • Refer to allergist: All patients with a history of systemic allergic reactions to Hymenoptera stings should be referred to an allergist for venom-specific testing and consideration of venom immunotherapy.
• Pitfalls:
  • Delaying epinephrine: The most dangerous mistake in anaphylaxis management.
  • Inadequate fluid resuscitation: Hypotension in anaphylaxis is often multifactorial, including relative hypovolemia.
  • Over-reliance on antihistamines/corticosteroids: These are adjuncts, not first-line treatments for anaphylaxis. They do not prevent or reverse life-threatening respiratory or cardiovascular symptoms.
  • Discharging too early: Leading to missed biphasic reactions.
  • Not prescribing or educating on auto-injectors: Leaving patients vulnerable to future severe reactions.

Recent Updates

• Guidelines: Current guidelines from organizations like the American Academy of Allergy, Asthma & Immunology (AAAAI), World Allergy Organization (WAO), and European Academy of Allergy and Clinical Immunology (EAACI) emphasize:
  • The paramount importance of prompt epinephrine administration for anaphylaxis.
  • The strong recommendation for venom immunotherapy (VIT) for patients with a history of systemic reactions, including those with mastocytosis.
  • Revised criteria for diagnosing anaphylaxis, often requiring involvement of two or more organ systems.
• Evidence:
  • Ongoing research continues to refine VIT protocols, including ultrarush and cluster immunotherapies for faster desensitization.
  • Growing recognition of mast cell disorders as a significant risk factor for severe Hymenoptera anaphylaxis, leading to recommendations for baseline tryptase screening in patients with severe reactions.
  • Increased focus on shared decision-making regarding VIT duration, weighing patient preference, risk factors, and venom-specific IgE levels.
• Controversies:
  • Optimal duration of VIT: While 3-5 years is standard, the optimal duration for high-risk patients (e.g., mastocytosis) is still debated, with some evidence supporting longer treatment.
  • Role of H2-antihistamines in acute anaphylaxis: While commonly used, strong evidence for their significant benefit in acute, severe anaphylaxis is limited, but they are generally harmless as adjuncts.
  • Specific cut-off values for venom-specific IgE or skin test results: Interpretation often requires clinical correlation.

Key References

1. Golden, D.B.K. (2020). Epidemiology of Hymenoptera venom allergy. Current Opinion in Allergy and Clinical Immunology, 20(4), 362-368.
2. Golden, D.B.K., et al. (2017). Stinging insect hypersensitivity: A practice parameter update 2017. Annals of Allergy, Asthma & Immunology, 118(1), P28-54.e1. (Major guidelines)
3. Muraro, A., et al. (2014). Anaphylaxis: Guidelines from the European Academy of Allergy and Clinical Immunology. Allergy, 69(8), 1026-1045.
4. Lieberman, P., et al. (2015). Anaphylaxis – a practice parameter update 2015. Annals of Allergy, Asthma & Immunology, 115(5), 341-382.
5. Shaker, M.S., et al. (2020). Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations Assessment, Development and Evaluation (GRADE) analysis. Journal of Allergy and Clinical Immunology, 145(6), 1699-1738.
6. Rueff, F., et al. (2015). The role of Hymenoptera venom allergy in mastocytosis. Current Opinion in Allergy and Clinical Immunology, 15(4), 361-366.
7. Brown, S.G.A., et al. (2013). International consensus on allergy diagnosis and management: Anaphylaxis. Allergy, 68(11), 1324-1335.
8. Joint Task Force on Practice Parameters (2011). The diagnosis and management of anaphylaxis: An updated practice parameter. Journal of Allergy and Clinical Immunology, 127(3), 587-593.e1. (Landmark review on anaphylaxis management)